Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/7/2015 |
| Start Date: | October 2010 |
| Contact: | Biogen-Idec Investigator |
| Email: | neurologyclinicaltrials@biogenidec.com |
The purpose of this study is to explore host genetic mutations which may render individual
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid
(DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide
information about viral genotypes that may be associated with higher pathogenicity, and help
to identify individuals who may be at higher risk of developing Progressive Multifocal
Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC
Virus (JCV).
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid
(DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide
information about viral genotypes that may be associated with higher pathogenicity, and help
to identify individuals who may be at higher risk of developing Progressive Multifocal
Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC
Virus (JCV).
The purpose of this study is to explore host genetic mutations which may render individual
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Deoxyribonucleic acid (DNA) will be analyzed from
natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML).
The genetic analysis of the subjects will directly seek mutations that could identify
subjects at risk.
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Deoxyribonucleic acid (DNA) will be analyzed from
natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML).
The genetic analysis of the subjects will directly seek mutations that could identify
subjects at risk.
Inclusion Criteria:
- Approximately 50 subjects with Multiple Sclerosis (MS) or Crohn's Disease (CD) who
develop Progressive Multifocal Leukoencephalopathy (PML) while receiving natalizumab
treatment
We found this trial at
11
sites
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Aurora, Colorado 80045
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials